Continue sua leitura
[ASCO 2014] Tumores Neuroendócrinos
Apoio:
A equipe do MOC selecionou os abstracts de maior impacto da ASCO 2014. Veja abaixo os destaques em Tumores Neuroendócrinos:
Tumors Neuroendócrinos
- Octreotide LAR (OCT-L) among elderly patients with stage IV neuroendocrine tumors (NETs): A survival analysis of SEER-Medicare data
- Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study
- The association between octreotide dose and tumor control in gastroenteropancreatic neuroendocrine tumors (NETs)
Tumor Neuroendócrino
Octreotide LAR (OCT-L) among elderly patients with stage IV neuroendocrine tumors (NETs): A survival analysis of SEER-Medicare data
Abstract No: 4112
Author(s): Chan Shen, Ya-Chen T. Shih, Ying Xu, James C. Yao; et al. Conclusions: This population-based study suggests potential survival benefits for use of OCT-L among elderly stage IV NET patients with or without secretory syndrome.
Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study
Abstract No: 4107^
Author(s): Martyn E. Caplin, Philippe B. Ruszniewski, Marianne E. Pavel, et al.
88 pts from the CLARINET core study (LAN arm, 41; PBO arm, 47) participated in OLE. At core study enrollment, 96% of OLE patients did not have tumor progression; 38% had pancreatic primary tumors, 39% had midgut, and 8% hindgut. The median PFS for LAN was reached during the OLE: 32.8 months. For subset of pts who had PD while on PBO in the core study, median time to further PD with LAN in the OLE was 14.0 months. During the OLE, 27% who continued LAN vs 40% switched to LAN had treatment-related adverse events (TRAE); most frequent TRAE was diarrhea. No new safety concerns were identified in the extension. Conclusions: CLARINET extension data suggest there were antitumor effects with LAN 120 mg in enteropancreatic NET patients with progressive disease. Long-term safety/tolerability of lanreotide in the extension was consistent with its known profile.
The association between octreotide dose and tumor control in gastroenteropancreatic neuroendocrine tumors (NETs)
Abstract No: 4108
Author(s): Sally C Lau, Winson Y. Cheung; et al.
A total of 170 patients were included: mean age 60 years (SD=13) and 54% were men. NETs most commonly originated from the midgut (47%) and the pancreas (21%). A significant proportion had unresectable, metastatic disease (81%) among whom the majority (87%) had hepatic involvement. Carcinoid symptoms that included diarrhea, flushing and wheezing were prevalent (72%). Octreotide was offered to patients with the intent of symptom management (71%), disease stabilization (23%), and tumor marker control (6%). The mean dose per 28-day cycle was 27 mg (SD=9). After accounting for symptoms and tumor burden, patients who received > 27 mg (n=78) experienced significantly longer median OS when compared to those who received </= 27 mg (n=92) of octreotide (82 vs. 39 months, respectively, p<0.0001). Likewise, median OS was also superior among those who were given > 30 mg (n=65) of octreotide as per the PROMID study, relative to those on </= 30 mg (n=105) of the drug (83 vs. 46 months, p=0.0001). Conclusions: Our findings suggest that higher doses of octreotide may confer OS benefits in selected patients with gastroenteropancreatic NETs and that titration of this drug to manage symptoms may not represent the optimal treatment strategy for all patients.